Study on Zanubrutinib for Patients with B-Cell Lymphoma Who Cannot Tolerate Previous BTK Inhibitor Treatments

Inclusion Criteria

• Must have a type of B-cell lymphoma that required treatment before starting ibrutinib or acalabrutinib.
• Must have experienced intolerable side effects from ibrutinib or acalabrutinib, such as:
  • Non-blood related side effects that are moderate or severe and last more than 7 days.
  • Severe non-blood related side effects of any length.
  • Severe low white blood cell count with infection or fever.
  • Very severe blood-related side effects that led to stopping the treatment.
  • For acalabrutinib only: mild side effects that happen repeatedly or last more than 7 days, or inability to use certain medications due to acalabrutinib.
• Side effects from previous treatments must have improved to mild or gone back to normal before starting zanubrutinib.
• Must be in good general health with a performance status score of 0, 1, or 2.
• Must have adequate blood cell counts before starting zanubrutinib.

Exclusion Criteria

• Have serious heart problems, such as a recent heart attack, unstable chest pain, severe heart failure, or certain heart rhythm issues.
• Have a history of bleeding in the brain.
• Have worsening disease while on ibrutinib or acalabrutinib.
• Have received other cancer treatments recently, within 7 days for most therapies or 4 weeks for immunotherapy.
• Need to take more than 10 mg of prednisone or equivalent corticosteroid daily. Must stop systemic corticosteroids at least 5 days before starting the study drug.